XML 61 R52.htm IDEA: XBRL DOCUMENT v3.20.2
Omeclamox®-Pak, RediTrex® and Vibativ® - Vibativ Acquisition - Schedule of Contingent Consideration and Preliminary Allocation (Details) - USD ($)
 1 Months Ended 2 Months Ended 12 Months Ended
Mar. 08, 2019
Nov. 30, 2018
Dec. 31, 2018
Dec. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Business Acquisition [Line Items]              
Cash paid at closing         $ 5,000,000 $ 20,000,000 $ 0
Goodwill     $ 784,000 $ 784,000 882,000 784,000  
VIBATIV              
Business Acquisition [Line Items]              
Cash paid at closing   $ 20,000,000.0     20,000,000    
Cash payment during early 2019 $ 5,000,000.0       5,000,000    
Fair value of contingent consideration - net sales royalty         9,182,000    
Total consideration         34,182,000    
Balance at November 12, 2018     9,034,000   9,502,000    
Change in fair value of contingent consideration included in operating expenses     (40,000)   (804,167)    
Contingent consideration earned and accrued in operating expenses       508,000 820,864    
Adjustment to initial fair value of the contingent consideration liability         148,000    
Cash payment of royalty during the period         1,033,108    
Balance at December 31, 2018     $ 9,502,000 $ 9,502,000 $ 8,633,589 $ 9,502,000  
Finished goods inventory   6,624,000          
Work in process - unlabeled vials   3,970,000          
Work in process - validation vials   1,827,000          
Raw materials   9,129,000          
Total inventory   21,550,000          
Intellectual property amortizable intangible assets   11,750,000          
Goodwill   882,000          
Total intangibles and goodwill   12,632,000          
Total assets acquired   $ 34,182,000